Search
Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigationalEtonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and F...
Tizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalTizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injur...
Zolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigationalZolbetuximab (previously claudiximab) is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived from human IgG1. It is specifically ta...
Synonyms: immunoglobulin G1, anti-(human Claudin-18.2) (human-mus musculus monoclonal IMAB362 heavy chain), disulfide with human-mus musculus monoclonal IMAB362 .kappa.-chain, dimerHyperforin
go.drugbank.com/drugs/DB01892InvestigationalNutraceuticalOne of the most important members of this family, due to its medical properties, is _Hypericum perforatum_, also known as St John's wort.
Dimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigational[L32995] Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. … [A233130] Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyllinate, is indicated to prevent nausea, vomiting, and dizziness caused by motion sickness.
Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigationalEculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. Eculizumab was granted FD...
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...